This transaction was conducted under a durable automatic sale instruction plan that Paulson adopted in June 2021. The sale was broker-assisted and aimed at covering the withholding tax liability incurred upon the vesting of restricted stock units, rather than representing a discretionary trade by Paulson. Following this transaction, Paulson retains ownership of 1,124,257 shares in the company. For deeper insights into KPTI's financial health and detailed analysis, including 10 key ProTips, check out the comprehensive Pro Research Report available on InvestingPro. For deeper insights into KPTI's financial health and detailed analysis, including 10 key ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
This transaction was conducted under a durable automatic sale instruction plan that Paulson adopted in June 2021. The sale was broker-assisted and aimed at covering the withholding tax liability incurred upon the vesting of restricted stock units, rather than representing a discretionary trade by Paulson. Following this transaction, Paulson retains ownership of 1,124,257 shares in the company.
In other recent news, Karyopharm Therapeutics (NASDAQ:KPTI) has reported significant developments in its operations. The company unveiled updates on its Phase 3 trials, including the SENTRY trial for myelofibrosis and the ECO-042 trial for endometrial cancer, both targeting annual U.S. peak revenues of $1 billion. Karyopharm also reported Q3 2024 revenues of $38.8 million and narrowed its 2024 revenue guidance to $145 million to $155 million.
In addition to these updates, the company announced leadership changes with Lori Macomber appointed as Executive Vice President, Chief Financial Officer, and Treasurer, and Kristin Abate promoted to Vice President, Chief Accounting Officer, and Assistant Treasurer.
These recent developments indicate Karyopharm's ongoing efforts to strengthen its executive team and progress in its clinical trials. The company is preparing for potential rapid launches of selinexor, pending approval, in both myelofibrosis and endometrial cancer markets. Despite a slight decline in net U.S. XPOVIO revenue compared to the previous year, the company maintains consistent growth in net product revenue. These developments reflect Karyopharm's resilience and strategic focus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.